01/09/2026
Pharma-led direct-to-patient (DTP) models are reshaping the GLP-1 access game for patients. Our 43rd Sermo Barometer, based on insights from over 950 HCPs, reveals a massive shift in how these treatments are accessed.
Here's the scoop:
When insurance denies GLP-1 coverage, over half of HCPs view pharma DTP as the most clinically acceptable self-pay option, ranking it above telehealth and medical spas.
HCPs are divided on pharma's growing role. Some support companies prescribing directly, while others insist on primary HCP oversight.
These new access points are game-changers for convenience, but they also ignite crucial debates about clinical oversight and care fragmentation.
🔍 Explore the data to see where weight loss treatment is headed